Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

NCT02374099 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: CC-486
DRUG: Fulvestrant

Sponsor

Celgene